Pfizer Announces CFO Transition as Dave Denton Exits Company

Date:

Share post:

On 18th June Pfizer Inc. (NYSE: PFE) the American Pharmaceuticals major announced that Dave Denton currently working as Chief Financial Officer (CFO) will step down from his current role and leave the company on August 15 for a professional opportunity outside of the pharmaceutical industry in consumer goods, which he hasmaintained. The company has named Cecile Guegan, currently appointed as Senior Vice President, Finance, Global Biopharmaceutical Business, will act as Interim CFO, effective from August 16, while the company will conduct a comprehensive internal and external search for its new CFO role. Both Dave and Cecile will work together to ensure a seamless transition.

Chairman and Chief Executive Officer of Pfizer Albert Bourla said “Dave has been a steady and trusted steward of Pfizer’s financial health, and we are grateful for his leadership, especially during some of the most important business transactions in our recent history, including Seagen, Biohaven, and Metsera, that will serve Pfizer well for years to come. We wish him the very best as he returns to the consumer goods industry,”. He also added “Given Cecile’s deep institutional knowledge and financial acumen, I have every confidence in her ability to lead Pfizer’s finance organization and keep us focused on what matters most – executing our strategy and delivering for patients and shareholders.”

Companies interim CFO Cecile holds a Master in Business degree from Brest Business School and she also has more than two decades of experience at Pfizer, amassing deep global financial experience leading finance across a wide range of complex and strategic portfolios, research and development, and several regions. In her current role, she is directly responsible for the financial operations and reporting of Pfizer’s biopharmaceutical business across all therapeutic areas and geographies. She has strong financial judgement and a proven track record of leading important enterprise initiatives, including the integration of Seagen into Pfizer in 2024.

Written by: Pramit Hazra

Graphics by: Pramit Hazra

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related articles

Bhawanipur Global Campus Announces iNATCONPH 2026: A Global Platform for Pharmacy & Allied Health Research

Kolkata: Bhawanipur Global Campus has announced the 16th International Conference - iNATCONPH 2026, a prestigious international scientific conference...

Emcure Pharma Receives CDSCO Approval to Launch Poviztra®️ for Fatty Liver Disease Treatment

Emcure Pharmaceuticals Ltd  announced that its co-marketed semaglutide brand, Poviztra®, has received regulatory approval from the Central Drugs...

CDSCO Partners with THSTI to Strengthen Vaccine and Healthcare innovation

The Central Drugs Standard Control Organization (CDSCO), India’s national regulatory authority, and the Translational Health Science and Technology...

EMeRG Launches Hospital Intel Suite™️ to transform MedTech Market

EMeRG, a leading healthcare intelligence provider with over a decade of industry expertise,  announced the launch of Hospital...